FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 340:901-907 March 25, 1999 Number 12 Next

	Full Text PDF Editorial by Schafer, A. I. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Patients who have a first episode of venous thromboembolism in the absence of known risk factors for thrombosis (idiopathic thrombosis) are often treated with anticoagulant therapy for three months. Such patients may benefit from longer treatment, however, because they appear to have an increased risk of recurrence after anticoagulant therapy is stopped.

Methods In this double-blind study, we randomly assigned patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism to continue receiving warfarin, with the dose adjusted to achieve an international normalized ratio of 2.0 to 3.0, or to receive placebo for a further 24 months. Our goal was to determine the effects of extended anticoagulant therapy on rates of recurrent symptomatic venous thromboembolism and bleeding.

Results A prespecified interim analysis of efficacy led to the early termination of the trial after 162 patients had been enrolled and followed for an average of 10 months. Of 83 patients assigned to continue to receive placebo, 17 had a recurrent episode of venous thromboembolism (27.4 percent per patient-year), as compared with 1 of 79 patients assigned to receive warfarin (1.3 percent per patient-year, P<0.001). Warfarin resulted in a 95 percent reduction in the risk of recurrent venous thromboembolism (95 percent confidence interval, 63 to 99 percent). Three patients assigned to the warfarin group had nonfatal major bleeding (two had gastrointestinal bleeding and one genitourinary bleeding), as compared with none of those assigned to the placebo group (3.8 percent vs. 0 percent per patient-year, P=0.09).

Conclusions Patients with a first episode of idiopathic venous thromboembolism should be treated with anticoagulant agents for longer than three months.

Source Information

From McMaster University, Hamilton, Ont., Canada (C.K., M.G., J.H., J.W., A.G.T., J.S.G., B.M., J.A.J.); Hamilton Civic Hospitals Research Centre, Hamilton, Ont., Canada (C.K., M.G., J.H., A.G.T., J.S.G., B.M.); the University of Western Ontario, London, Ont., Canada (M.J.K.); Dalhousie University, Halifax, N.S., Canada (D.R.A.); Northwestern University Medical School, Chicago (D.G.); and the University of Ottawa, Ottawa, Ont., Canada (P.W.). Other authors were Marilyn Johnston, A.R.T., Hamilton Civic Hospitals Research Centre, Hamilton, Ont.; James Douketis, M.D., and Robin Roberts, M.Tech., McMaster University, Hamilton, Ont.; Paul van Nguyen, M.D., and Jeannine Kassis, M.D., University of Montreal, Montreal; Sean Dolan, M.D., University of New Brunswick, St. John, N.B.; Christine Demers, M.D., and Louis Desjardins, M.D., Laval University, Quebec, Que.; Susan Solymoss, M.D., McGill University, Montreal — all in Canada; and Arthur Trowbridge, M.D., Texas A&M University, Temple.The institutions that participated in the study are listed in the Appendix.

Address reprint requests to Dr. Kearon at the Hamilton Health Sciences Corporation, Henderson Division, 711 Concession St., Hamilton, ON L8V 1C3, Canada.

Full Text of this Article

Related Letters:

Anticoagulation for Venous Thromboembolism
Bucciarelli P., Alatri A., Moia M., Khamashta M. A., Williams F. M.K., Hunt B. J., Kearon C., Ginsberg J. S., Gent M.
Extract | Full Text  
N Engl J Med 1999; 341:539-540, Aug 12, 1999. Correspondence

This article has been cited by other articles:

• Imfeld, S., Staub, D., Uthoff, H., Baldi, T., Aschwanden, M., Jaeger, K. A. (2009). Ultrasonography to Guide Duration of Anticoagulation in DVT. ANN INTERN MED 151: 826-826 [Full Text]  
• Lijfering, W. M., Veeger, N. J. G. M., Middeldorp, S., Hamulyak, K., Prins, M. H., Buller, H. R., van der Meer, J. (2009). A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 114: 2031-2036 [Abstract] [Full Text]  
• Giannakopoulos, B., Krilis, S. A. (2009). How I treat the antiphospholipid syndrome. Blood 114: 2020-2030 [Abstract] [Full Text]  
• Sanchez, O., Planquette, B., Meyer, G. (2009). Update on acute pulmonary embolism. ERR 18: 137-147 [Full Text]  
• Segal, J. B., Brotman, D. J., Necochea, A. J., Emadi, A., Samal, L., Wilson, L. M., Crim, M. T., Bass, E. B. (2009). Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation: A Systematic Review. JAMA 301: 2472-2485 [Abstract] [Full Text]  
• Cios, D. A., Baker, W. L., Sander, S. D., Phung, O. J., Coleman, C. I. (2009). Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis. Am J Health Syst Pharm 66: 916-925 [Abstract] [Full Text]  
• Garcia, D. A (2009). Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped. Evid. Based Med. 14: 59-59 [Full Text]  
• Zhu, T., Martinez, I., Emmerich, J. (2009). Venous Thromboembolism: Risk Factors for Recurrence. Arterioscler. Thromb. Vasc. Bio. 29: 298-310 [Abstract] [Full Text]  
• Schellong, S. M., Bounameaux, H., Büller, H. R. (2009). CHAPTER 37 Venous Thromboembolism. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Kearon, C., Julian, J. A., Kovacs, M. J., Anderson, D. R., Wells, P., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., Gent, M., Ginsberg, J. S., for the ELATE Investigators, (2008). Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 112: 4432-4436 [Abstract] [Full Text]  
• Ibrahim, S. A., Stone, R. A., Obrosky, D. S., Geng, M., Fine, M. J., Aujesky, D. (2008). Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism. Arch Intern Med 168: 2183-2190 [Abstract] [Full Text]  
• Glueck, C. J., Freiberg, R. A., Boppana, S., Wang, P. (2008). Thrombophilia, Hypofibrinolysis, the eNOS T-786C Polymorphism, and Multifocal Osteonecrosis. JBJS 90: 2220-2229 [Abstract] [Full Text]  
• Kearon, C. MB PhD (2008). Stopping anticoagulant therapy after an unprovoked venous thromboembolism. CMAJ 179: 401-402 [Full Text]  
• Rodger, M. A. MD MSc, Kahn, S. R. MD MSc, Wells, P. S. MD MSc, Anderson, D. A. MD, Chagnon, I. MD, Le Gal, G. MD PhD, Solymoss, S. MD, Crowther, M. MD, Perrier, A. MD, White, R. MD, Vickars, L. MD, Ramsay, T. PhD MSc, Betancourt, M. T. MD MSc, Kovacs, M. J. MD (2008). Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179: 417-426 [Abstract] [Full Text]  
• Siragusa, S., Malato, A., Anastasio, R., Cigna, V., Milio, G., Amato, C., Bellisi, M., Attanzio, M. T., Cormaci, O., Pellegrino, M., Dolce, A., Casuccio, A., Bajardi, G., Mariani, G. (2008). Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 112: 511-515 [Abstract] [Full Text]  
• Legnani, C., Palareti, G., Cosmi, B., Cini, M., Tosetto, A., Tripodi, A., for the PROLONG Investigators (on behalf of FCSA a, (2008). Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. haematol 93: 900-907 [Abstract] [Full Text]  
• Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full Text]  
• Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., Comerota, A. J. (2008). Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 454S-545S [Abstract] [Full Text]  
• Levi, M., Hovingh, G. K., Cannegieter, S. C., Vermeulen, M., Buller, H. R., Rosendaal, F. R. (2008). Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 111: 4471-4476 [Abstract] [Full Text]  
• MADHWAL, S., LINCOFF, A. M., ROLSTON, D. D.K. (2008). Q: Should patients on long-term warfarin take aspirin for heart disease?. Cleveland Clinic Journal of Medicine 75: 206-208 [Full Text]  
• Heit, J. A. (2008). The Epidemiology of Venous Thromboembolism in the Community. Arterioscler. Thromb. Vasc. Bio. 28: 370-372 [Full Text]  
• Bounameaux, H., Perrier, A. (2008). Duration of Anticoagulation Therapy for Venous Thromboembolism. ASH Education Book 2008: 252-258 [Abstract] [Full Text]  
• Franke, C. A., Dickerson, L. M., Carek, P. J. (2008). Improving Anticoagulation Therapy Using Point-of-Care Testing and a Standardized Protocol. Ann Fam Med 6: S28-S32 [Abstract] [Full Text]  
• Garcia, D. A., Khamashta, M. A., Crowther, M. A. (2007). How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 110: 3122-3127 [Abstract] [Full Text]  
• Galli, M., Borrelli, G., Jacobsen, E. M., Marfisi, R. M., Finazzi, G., Marchioli, R., Wisloff, F., Marziali, S., Morboeuf, O., Barbui, T. (2007). Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110: 1178-1183 [Abstract] [Full Text]  
• Marchiori, A., Mosena, L., Prins, M. H., Prandoni, P. (2007). The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. haematol 92: 1107-1114 [Abstract] [Full Text]  
• Koscielny, J., Kiesewetter, H., Jorg, I., Harenberg, J. (2007). Ximelagatran for Treatment and Prophylaxis of Recurrent Events in Deep Vein Thrombosis. CLIN APPL THROMB HEMOST 13: 299-307 [Abstract]  
• Oake, N., Fergusson, D. A., Forster, A. J., van Walraven, C. (2007). Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 176: 1589-1594 [Abstract] [Full Text]  
• Campbell, I A, Bentley, D P, Prescott, R J, Routledge, P A, Shetty, H G M, Williamson, I J (2007). Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 334: 674-674 [Abstract] [Full Text]  
• Snow, V., Qaseem, A., Barry, P., Hornbake, E. R., Rodnick, J. E., Tobolic, T., Ireland, B., Segal, J. B., Bass, E. B., Weiss, K. B., Green, L., Owens, D. K., and the Joint American College of Physicians/Ameri, (2007). Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. ANN INTERN MED 146: 204-210 [Abstract] [Full Text]  
• Segal, J. B., Streiff, M. B., Hofmann, L. V., Thornton, K., Bass, E. B. (2007). Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline. ANN INTERN MED 146: 211-222 [Abstract] [Full Text]  
• Prandoni, P., Noventa, F., Ghirarduzzi, A., Pengo, V., Bernardi, E., Pesavento, R., Iotti, M., Tormene, D., Simioni, P., Pagnan, A. (2007). The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. haematol 92: 199-205 [Abstract] [Full Text]  
• Snow, V., Qaseem, A., Barry, P., Hornbake, E. R., Rodnick, J. E., Tobolic, T., Ireland, B., Segal, J., Bass, E., Weiss, K. B., Green, L., Owens, D. K., The Joint American College Of Physicians/american, (2007). Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 5: 74-80 [Abstract] [Full Text]  
• Mismetti, P., Rivron-Guillot, K., Quenet, S., Decousus, H., Laporte, S., Epinat, M., Barral, F. G. (2007). A Prospective Long-term Study of 220 Patients With a Retrievable Vena Cava Filter for Secondary Prevention of Venous Thromboembolism. Chest 131: 223-229 [Abstract] [Full Text]  
• Rand, J. H. (2007). The Antiphospholipid Syndrome. ASH Education Book 2007: 136-142 [Abstract] [Full Text]  
• Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A. W.A., Tripodi, A., the PROLONG Investigators, (2006). D-Dimer Testing to Determine the Duration of Anticoagulation Therapy. NEJM 355: 1780-1789 [Abstract] [Full Text]  
• Miller, A., Campbell, I., Fennerty, T., Raskob, G. E., Buller, H. R. (2006). Duration of warfarin in pulmonary embolism.. Chest 130: 299-300 [Full Text]  
• van Walraven, C., Jennings, A., Oake, N., Fergusson, D., Forster, A. J. (2006). Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression. Chest 129: 1155-1166 [Abstract] [Full Text]  
• Ho, W. K., Hankey, G. J., Quinlan, D. J., Eikelboom, J. W. (2006). Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.. Arch Intern Med 166: 729-736 [Abstract] [Full Text]  
• Lim, W., Crowther, M. A., Eikelboom, J. W. (2006). Management of Antiphospholipid Antibody Syndrome: A Systematic Review. JAMA 295: 1050-1057 [Abstract] [Full Text]  
• Cirujeda, J. L., Granado, P. C. (2006). A Study on the Safety, Efficacy, and Efficiency of Sulodexide Compared with Acenocoumarol in Secondary Prophylaxis in Patients with Deep Venous Thrombosis. ANGIOLOGY 57: 53-64 [Abstract]  
• (2005). Additional Information. JAMA 294: E1-E3 [Full Text]  
• Aujesky, D., Smith, K. J., Cornuz, J., Roberts, M. S. (2005). Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism. Chest 128: 1601-1610 [Abstract] [Full Text]  
• Ost, D., Tepper, J., Mihara, H., Lander, O., Heinzer, R., Fein, A. (2005). Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis. JAMA 294: 706-715 [Abstract] [Full Text]  
• Ruiz-Irastorza, G., Khamashta, M. A. (2005). Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology (Oxford) 44: 971-974 [Abstract] [Full Text]  
• The PREPIC Study Group, (2005). Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) Randomized Study. Circulation 112: 416-422 [Abstract] [Full Text]  
• Gulseth, M. P. (2005). Ximelagatran: An orally active direct thrombin inhibitor. Am J Health Syst Pharm 62: 1451-1467 [Abstract] [Full Text]  
• Christiansen, S. C., Cannegieter, S. C., Koster, T., Vandenbroucke, J. P., Rosendaal, F. R. (2005). Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events. JAMA 293: 2352-2361 [Abstract] [Full Text]  
• Connor, J. A. (2005). Factor V Leiden and Its Effect on Children With Cardiac Pathology. Journal of Pediatric Oncology Nursing 22: 176-181 [Abstract]  
• Wells, P. S., Anderson, D. R., Rodger, M. A., Forgie, M. A., Florack, P., Touchie, D., Morrow, B., Gray, L., O'Rourke, K., Wells, G., Kovacs, J., Kovacs, M. J. (2005). A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Arch Intern Med 165: 733-738 [Abstract] [Full Text]  
• Hoppe, B., Tolou, F., Radtke, H., Kiesewetter, H., Dorner, T., Salama, A. (2005). Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 105: 1549-1551 [Abstract] [Full Text]  
• Hirsh, J., O'Donnell, M., Weitz, J. I. (2005). New anticoagulants. Blood 105: 453-463 [Abstract] [Full Text]  
• Becattini, C., Agnelli, G., Prandoni, P., Silingardi, M., Salvi, R., Taliani, M. R., Poggio, R., Imberti, D., Ageno, W., Pogliani, E., Porro, F., Casazza, F. (2005). A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 26: 77-83 [Abstract] [Full Text]  
• Goldhaber, S. Z. (2004). Prevention of Recurrent Idiopathic Venous Thromboembolism. Circulation 110: IV-20-IV-24 [Abstract] [Full Text]  
• Wittkowsky, A. K. (2004). Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism. Journal of Pharmacy Practice 17: 308-316 [Abstract]  
• Weitz, J. I., Hirsh, J., Samama, M. M. (2004). New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 265S-286S [Abstract] [Full Text]  
• Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]  
• Buller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., Raskob, G. E. (2004). Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 401S-428S [Abstract] [Full Text]  
• Kearon, C. (2004). Long-Term Management of Patients After Venous Thromboembolism. Circulation 110: I-10-I-18 [Abstract] [Full Text]  
• Weitz, J. I. (2004). New Anticoagulants for Treatment of Venous Thromboembolism. Circulation 110: I-19-I-26 [Abstract] [Full Text]  
• Augustinos, P., Ouriel, K. (2004). Invasive Approaches to Treatment of Venous Thromboembolism. Circulation 110: I-27-I-34 [Abstract] [Full Text]  
• Bates, S. M., Ginsberg, J. S. (2004). Treatment of Deep-Vein Thrombosis. NEJM 351: 268-277 [Full Text]  
• Kyrle, P. A., Minar, E., Bialonczyk, C., Hirschl, M., Weltermann, A., Eichinger, S. (2004). The Risk of Recurrent Venous Thromboembolism in Men and Women. NEJM 350: 2558-2563 [Abstract] [Full Text]  
• Goldhaber, S. Z., Nadel, E. S., King, M. E., Sharma, A. (2004). Case 17-2004 - A 42-Year-Old Woman with Cardiac Arrest Several Weeks after an Ankle Fracture. NEJM 350: 2281-2290 [Full Text]  
• Wilson, S. E., Watson, H. G., Crowther, M. A. (2004). Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 170: 821-824 [Abstract] [Full Text]  
• Kahn, S. R., Ginsberg, J. S. (2004). Relationship Between Deep Venous Thrombosis and the Postthrombotic Syndrome. Arch Intern Med 164: 17-26 [Abstract] [Full Text]  
• Eichinger, S., Weltermann, A., Minar, E., Stain, M., Schonauer, V., Schneider, B., Kyrle, P. A. (2004). Symptomatic Pulmonary Embolism and the Risk of Recurrent Venous Thromboembolism. Arch Intern Med 164: 92-96 [Abstract] [Full Text]  
• Lopez, J. A., Kearon, C., Lee, A. Y.Y. (2004). Deep Venous Thrombosis. ASH Education Book 2004: 439-456 [Abstract] [Full Text]  
• Goldhaber, S. Z., Elliott, C. G. (2003). Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention. Circulation 108: 2834-2838 [Full Text]  
• van Dongen, C. J., Vink, R., Hutten, B. A., Buller, H. R., Prins, M. H. (2003). Recurrent Thromboembolism After Treatment With Vitamin K Antagonists. Arch Intern Med 163: 2793-2793 [Full Text]  
• Linkins, L.-A., Choi, P. T., Douketis, J. D. (2003). Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis. ANN INTERN MED 139: 893-900 [Abstract] [Full Text]  
• Huisman, M. V., van der Meer, F. J.M., van Rooden, C. J., Malik, V., Kupfer, Y., Tessler, S., Tran, H. A., Brotman, D. J., Ridker, P. M., Goldhaber, S. Z., Glynn, R. J., Kearon, C., Julian, J. A., Ginsberg, J. S., Buller, H. R., Prins, M. H. (2003). Low-Intensity versus Conventional-Intensity Warfarin for Prevention of Recurrent Venous Thromboembolism. NEJM 349: 2164-2167 [Full Text]  
• Schulman, S., Wahlander, K., Lundstrom, T., Clason, S. B., Eriksson, H., the THRIVE III Investigators, (2003). Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. NEJM 349: 1713-1721 [Abstract] [Full Text]  
• Frazee, L. A, Chomo, D. L (2003). Duration of Anticoagulant Therapy After Initial Idiopathic Venous Thromboembolism. The Annals of Pharmacotherapy 37: 1489-1496 [Abstract] [Full Text]  
• Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., Clarke, A., Geerts, W., Forgie, M., Green, D., Costantini, L., Yacura, W., Wilson, S., Gent, M., Kovacs, M. J. (2003). A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome. NEJM 349: 1133-1138 [Abstract] [Full Text]  
• Heit, J. A. (2003). The Potential Role of Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism. Chest 124 : 40S-48S [Abstract] [Full Text]  
• Eichinger, S., Minar, E., Bialonczyk, C., Hirschl, M., Quehenberger, P., Schneider, B., Weltermann, A., Wagner, O., Kyrle, P. A. (2003). D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA 290: 1071-1074 [Abstract] [Full Text]  
• Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., Gent, M., the Extended Low-Intensity Anticoagulation for Thr, (2003). Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. NEJM 349: 631-639 [Abstract] [Full Text]  
• van Dongen, C. J.J., Prins, M. H., Buller, H. R., Seneviratne, C., Kupfer, Y., Tessler, S., Krishnan, J. A., Streiff, M. B., Cosmi, B., Palareti, G., Aberegg, S. K., Ridker, P. M., Goldhaber, S. Z., Glynn, R. J., the PREVENT Investigators, (2003). Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 349: 398-400 [Full Text]  
• Palareti, G., Legnani, C., Cosmi, B., Valdre, L., Lunghi, B., Bernardi, F., Coccheri, S. (2003). Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia. Circulation 108: 313-318 [Abstract] [Full Text]  
• Meroni, P L, Moia, M, Derksen, R H., Tincani, A, McIntyre, J A, Arnout, J M., Koike, T, Piette, J-C, Khamashta, M A, Shoenfeld, Y (2003). Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 12: 504-507 [Abstract]  
• Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M. R., Miccio, M., Imberti, D., Poggio, R., Ageno, W., Pogliani, E., Porro, F., Zonzin, P., for the Warfarin Optimal Duration Italian Trial In, (2003). Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism. ANN INTERN MED 139: 19-25 [Abstract] [Full Text]  
• Kearon, C. (2003). Natural History of Venous Thromboembolism. Circulation 107: I-22-30 [Abstract] [Full Text]  
• Hyers, T. M. (2003). Duration of Anticoagulation in Venous Thromboembolism. Arch Intern Med 163: 1265-1266 [Full Text]  
• van Dongen, C. J. J., Vink, R., Hutten, B. A., Buller, H. R., Prins, M. H. (2003). The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event: A Meta-analysis. Arch Intern Med 163: 1285-1293 [Abstract] [Full Text]  
• (2003). British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58: 470-483 [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41: 1633-1652 [Full Text]  
• Wells, P. S., Forgie, M. A., Simms, M., Greene, A., Touchie, D., Lewis, G., Anderson, J., Rodger, M. A. (2003). The Outpatient Bleeding Risk Index: Validation of a Tool for Predicting Bleeding Rates in Patients Treated for Deep Venous Thrombosis and Pulmonary Embolism. Arch Intern Med 163: 917-920 [Abstract] [Full Text]  
• Ridker, P. M, Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., Glynn, R. J., the PREVENT Investigators, (2003). Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. NEJM 348: 1425-1434 [Abstract] [Full Text]  
• Schafer, A. I. (2003). Warfarin for Venous Thromboembolism -- Walking the Dosing Tightrope. NEJM 348: 1478-1480 [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 107: 1692-1711 [Full Text]  
• Streiff, M. B. (2003). Vena Caval Filters: A Review for Intensive Care Specialists. J Intensive Care Med 18: 59-79 [Abstract]  
• Galli, M., Luciani, D., Bertolini, G., Barbui, T. (2003). Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827-1832 [Abstract] [Full Text]  
• Deitcher, S. R, Gomes, M. P. (2003). Hypercoagulable state testing and malignancy screening following venous thromboembolic events. Vasc Med 8: 33-46 [Abstract]  
• Schafer, A. I., Levine, M. N., Konkle, B. A., Kearon, C. (2003). Thrombotic Disorders: Diagnosis and Treatment. ASH Education Book 2003: 520-539 [Abstract] [Full Text]  
• Prandoni, P., Lensing, A. W.A., Prins, M. H., Bernardi, E., Marchiori, A., Bagatella, P., Frulla, M., Mosena, L., Tormene, D., Piccioli, A., Simioni, P., Girolami, A. (2002). Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism. ANN INTERN MED 137: 955-960 [Abstract] [Full Text]  
• Bates, S. M., Ginsberg, J. S. (2002). How we manage venous thromboembolism during pregnancy. Blood 100: 3470-3478 [Abstract] [Full Text]